Eichenauer Dennis A, Borchmann Peter
First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany.
German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany.
Leuk Lymphoma. 2025 May;66(5):830-837. doi: 10.1080/10428194.2024.2447886. Epub 2025 Jan 2.
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity accounting for ≈5% of all Hodgkin lymphoma (HL) cases. As some characteristics of NLPHL resemble B-cell non-Hodgkin lymphoma (B-NHL), nodular lymphocyte-predominant B-cell lymphoma has been proposed as alternative name. Unlike classical HL (cHL), NLPHL is mostly diagnosed in early stages. The clinical course is usually indolent. Overall, NLPHL patients have an excellent prognosis and the majority experiences long-term survival. Except for stage IA disease which is sufficiently treated with radiotherapy alone, treatment of newly diagnosed NLPHL is often very similar to cHL. However, activity has also been demonstrated for rituximab-containing protocols applied in B-NHL. Second-line treatment is chosen individually and mostly less intensive than in cHL. Chimeric antigen receptor T-cell therapy and bispecific antibodies may be part of future treatment strategies for NLPHL. This review aims at summarizing recent data on treatment approaches and discussing future perspectives in NLPHL.
结节性淋巴细胞为主型霍奇金淋巴瘤（NLPHL）是一种罕见的淋巴瘤实体，约占所有霍奇金淋巴瘤（HL）病例的5%。由于NLPHL的一些特征与B细胞非霍奇金淋巴瘤（B-NHL）相似，因此有人提出将结节性淋巴细胞为主型B细胞淋巴瘤作为替代名称。与经典型HL（cHL）不同，NLPHL大多在早期被诊断出来。其临床病程通常较为惰性。总体而言，NLPHL患者预后良好，大多数患者可长期存活。除了IA期疾病单独放疗即可充分治疗外，新诊断的NLPHL的治疗通常与cHL非常相似。然而，含利妥昔单抗的方案在B-NHL中的应用也已显示出活性。二线治疗是个体化选择的，大多比cHL的治疗强度小。嵌合抗原受体T细胞疗法和双特异性抗体可能是NLPHL未来治疗策略的一部分。本综述旨在总结NLPHL治疗方法的最新数据，并讨论其未来前景。
